The inhibition of deubiquitination and oxidative stress

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K16405
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: Fujita Health University (2022); Keio University (2021)
• Principal Investigator: Otsuki Yuji 藤田医科大学, 医科学研究センター, 研究員 (10875412)
• Project Period (FY): 2021-04-01 – 2023-03-31
• Keywords: がん / ユビキチン

Outline of Final Research Achievements

In this study, we aim to reveal the mechanism in relationship of the antioxidant system in many type of resistant tumors and the association of certain ubiquitin-selective proteases (USPs) with cancer malignancy. This suggests that the findings of this research have a high potential for universal application in various types of cancer, and thus, the research significance is considered to be very high.
During this development, it was revealed that the inhibition of deubiquitinase (DUB) enzymes and the ubiquitin-selective proteases (USPs) of DUB-related proteins could potentially control aldehyde metabolism within cancer cells. It was also identified that gene X, which could be associated with both aldehyde metabolism and DUB, might exist.

Free Research Field

腫瘍生物学

Academic Significance and Societal Importance of the Research Achievements

本開発により、酸化ストレスとがんの治療抵抗性に関わるメカニズムの解明が進むことで、新規のがん治療の創出や現行治療の対象患者の選定方法、および現行治療効果の予後改善につながる研究が創出されることが期待される。これにより、より安全で効果の高いがん治療の創出につながることが予想され、がん患者へより良い治療が届けられるようになると考えられる。